Quest Diagnostics (NYSE:DGX) is partnering with Guardant Health to offer Shield, an FDA-approved blood test for colorectal ...

Quest Diagnostics is a dominant player in the growing medical testing industry, offering consistent earnings and dividend growth with lower volatility. DGX benefits from secular tailwinds like aging ...

What Quest Diagnostics’ recent performance tells you Quest Diagnostics (DGX) has attracted fresh attention after recent share ...

Quest Diagnostics will soon begin offering a new blood-based in-vitro diagnostic test for Alzheimer’s. The disease affects nearly 7 million Americans. The Lumipulse G pTau 217/β-Amyloid 1-42 Plasma ...

Quest Diagnostics recently unveiled a suite of advanced diagnostics and support services designed to broaden access to lab tests for transplants. Quest hopes to improve testing compliance among ...

Quest Diagnostics named Dr. Yuri Fesko, a seasoned health care executive and oncologist, its new senior vice president and chief medical officer. In a Dec. 20 press release announcing the appointment, ...

Quest Diagnostics and Elevance Health are broadening their partnership into four more states with the goal of making it easier for patients to access in-network laboratory services. Beginning Jan. 1, ...

Quest Diagnostics is building out its artificial intelligence-powered cancer pathology offerings through a multilayered deal with PathAI—acquiring some assets and licensing out others. The testing ...

Quest Diagnostics DGX is well-poised to grow in the coming quarters owing to its investments in advanced diagnostics to deliver and scale innovative services. The company’s growth strategy includes ...

James Davis, Chairman, CEO & President, stated that "Our third quarter performance underscores strong demand for our clinical solutions, our diligent execution to meet customer needs and our ...